(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 57.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Geron's revenue in 2025 is $116,293,000.On average, 5 Wall Street analysts forecast GERN's revenue for 2025 to be $126,153,026,492, with the lowest GERN revenue forecast at $116,415,827,807, and the highest GERN revenue forecast at $131,205,058,148. On average, 5 Wall Street analysts forecast GERN's revenue for 2026 to be $193,764,394,174, with the lowest GERN revenue forecast at $169,668,521,554, and the highest GERN revenue forecast at $215,749,521,345.
In 2027, GERN is forecast to generate $298,520,168,586 in revenue, with the lowest revenue forecast at $226,456,108,857 and the highest revenue forecast at $373,182,852,767.